JP5756758B2 - システイン非含有で有効なテクネチウム（Ｔｃ）又はレニウム（Ｒｅ）のキレート化ペプチドタグ及びその使用 - Google Patents

システイン非含有で有効なテクネチウム（Ｔｃ）又はレニウム（Ｒｅ）のキレート化ペプチドタグ及びその使用 Download PDF

Info

Publication number
JP5756758B2
JP5756758B2 JP2011542921A JP2011542921A JP5756758B2 JP 5756758 B2 JP5756758 B2 JP 5756758B2 JP 2011542921 A JP2011542921 A JP 2011542921A JP 2011542921 A JP2011542921 A JP 2011542921A JP 5756758 B2 JP5756758 B2 JP 5756758B2
Authority
JP
Japan
Prior art keywords
tco
seq
peptide
protein
ubi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011542921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513980A (ja
JP2012513980A5 (enExample
Inventor
クランシュ，ロイック ル
クランシュ，ロイック ル
ルコック，アラン
ジン−ジャスティン，ソフィー
タイ，ロバート
マセラ，ミシェル
キュニアッス，フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Publication of JP2012513980A publication Critical patent/JP2012513980A/ja
Publication of JP2012513980A5 publication Critical patent/JP2012513980A5/ja
Application granted granted Critical
Publication of JP5756758B2 publication Critical patent/JP5756758B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011542921A 2008-12-30 2009-12-28 システイン非含有で有効なテクネチウム（Ｔｃ）又はレニウム（Ｒｅ）のキレート化ペプチドタグ及びその使用 Expired - Fee Related JP5756758B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08291257.7 2008-12-30
EP08291257A EP2204377A1 (en) 2008-12-30 2008-12-30 Cysteine-free technetium (tc) or rhenium (re) chelating peptide tags and their use
PCT/IB2009/007971 WO2010076654A2 (en) 2008-12-30 2009-12-28 CYSTEINE-FREE EFFICIENT TECHNETIUM (Tc) OR RHENIUM (Re) CHELATING PEPTIDE TAGS AND THEIR USE

Publications (3)

Publication Number Publication Date
JP2012513980A JP2012513980A (ja) 2012-06-21
JP2012513980A5 JP2012513980A5 (enExample) 2013-02-07
JP5756758B2 true JP5756758B2 (ja) 2015-07-29

Family

ID=40578262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011542921A Expired - Fee Related JP5756758B2 (ja) 2008-12-30 2009-12-28 システイン非含有で有効なテクネチウム（Ｔｃ）又はレニウム（Ｒｅ）のキレート化ペプチドタグ及びその使用

Country Status (5)

Country Link
US (1) US9234001B2 (enExample)
EP (2) EP2204377A1 (enExample)
JP (1) JP5756758B2 (enExample)
CA (1) CA2745946A1 (enExample)
WO (1) WO2010076654A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949463B1 (fr) 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421735A (en) * 1980-04-17 1983-12-20 The Massachusetts General Hospital Radiolabeled diagnostic compositions and method for making the same
US5128119A (en) * 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
NL1006164C2 (nl) * 1997-05-29 1998-12-01 Univ Leiden Antimicrobiële peptiden.

Also Published As

Publication number Publication date
EP2382229B1 (en) 2013-07-24
US9234001B2 (en) 2016-01-12
EP2204377A1 (en) 2010-07-07
WO2010076654A3 (en) 2010-12-16
CA2745946A1 (en) 2010-07-08
WO2010076654A2 (en) 2010-07-08
EP2382229A2 (en) 2011-11-02
JP2012513980A (ja) 2012-06-21
US20110318827A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
HUT77137A (hu) Radionuklid-kelátképző peptidszármazékok
KR20170073611A (ko) Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
AU2019469641B2 (en) Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders
JP2000515514A (ja) 放射性金属元素結合ペプチドの類似化合物
JP7026784B2 (ja) ミニガストリン誘導体、特にｃｃｋ２受容体陽性腫瘍の診断及び／又は治療において使用するためのミニガストリン誘導体
Ishiguro et al. Complete amino acid sequence of human liver cytosolic alanine aminotransferase (GPT) determined by a combination of conventional and mass spectral methods
CN105848687A (zh) 放射性示踪剂组合物和方法
EP0515313A2 (en) Somatostatin analogues containing chelating groups and their radiolabeled compositions
CN105849067B (zh) 纯化方法和组合物
JP5756758B2 (ja) システイン非含有で有効なテクネチウム（Ｔｃ）又はレニウム（Ｒｅ）のキレート化ペプチドタグ及びその使用
Khachatryan et al. Synthesis of precursors for obtaining targeted radiopharmaceuticals based on short peptides, analogs of the hormone somatostatin
WO1995020603A1 (en) Inhibitors of serine proteases, bearing a chelating group
Hosseini et al. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs
Koźmiński et al. Labelling of peptides with 99m Tc complexes through the modified C-terminal group
EP1257575B1 (en) Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
CN119789878A (zh) 一种新的三功能化合物及其用途
EP1047708B1 (en) Peptide chelators that predominately form a single stereoisomeric species upon coordination to a metal center
US6334996B1 (en) Chelators that predominantely form a single stereoisomeric species upon coordination to a metal center
CN114845742A (zh) 用于癌症成像和治疗的经改性的grpr拮抗剂肽
WO2025179168A1 (en) Synthesis of dll3-binding peptides
Klimentzou et al. Solid‐phase Synthesis of a Peptide Derivative of Thymosin alpha1 and Initial Studies on its 99mTc‐Radiolabelling
Tang et al. Synthesis of small peptides and their use as bifunctional chelating agents in diagnostic radiopharmaceuticals
US20060111552A1 (en) Metal binding precursors for the synthesis of peptide-metal conjugates
Oza Cyclization of peptide structures by creating metal foldamers using 99m-Tc/Re (CO) 3
Shenoy Investigation of the replacement of cysteine residues in DOTA-(Tyr³)-octreotate: synthesis, characterization and evaluation of biological activities

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150601

R150 Certificate of patent or registration of utility model

Ref document number: 5756758

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees